Advertisement

Rapid Readouts

onclive rapid readouts logo

OncLive presents Rapid Readouts. In each video, leading experts in their field present slides and posters from annual oncology conferences, symposiums, and meetings, highlighting the everchanging landscape of treatment choices for patient management.

Select Conference:
World Conference on Lung Cancer
ASCO
phase 3 trial
Phase 3 Randomized Study Of Momelotinib Versus Danazol
Elacestrant Vs Standard Endocrine
Epcoritamab + Gemcitabine + Oxaliplatin in DLBCL transplant ineligible patients induces high response rate
Primary Results From Tropics 02
ESMO
ASH
AACR
SABCS
World GI
Select Year:
2021
2022
2020

Phase 1/2 Study of Mobocertinib in mNSCLC With EGFR Exon 20 Insertions: EXCLAIM and Platinum-Pretreated Patients Cohorts

February 19th, 2021

Rapid Readouts: Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-Naïve Chronic Lymphocytic Leukemia: ELEVATE-TN 4-Year Follow-up

July 8th, 2021

ATHENA–MONO (GOG-3020/ENGOT-ov45): A randomized, double-blind, phase 3 trial evaluating rucaparib monotherapy versus placebo as maintenance treatment following response to first-line platinum-based chemotherapy in ovarian cancer

June 22nd, 2022

MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor

June 23rd, 2022

Elacestrant (Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results from the Randomized Phase III EMERALD Trial

June 17th, 2022

Epcoritamab + Gemcitabine + Oxaliplatin in R/R DLBCL Transplant Ineligible Patients Induces High Response Rate Even in Pts Failing CAR T Therapy

June 24th, 2022

Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer

June 23rd, 2022

Updated Efficacy and Safety of Larotrectinib in Patients with Advanced Tropomyosin Receptor Kinase (TRK) Fusion Positive Thyroid Carcinoma

November 18th, 2022

Updated Results of APHINITY at 8.4 Years Median Follow Up

November 17th, 2022

Retrospective Analysis of Anemia Benefit of Pacritinib from the PERSIST-2 Trial

October 19th, 2022

Overall Survival Results From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan vs Treatment of Physician’s Choice in Patients With HR+/HER2– Metastatic Breast Cancer

October 18th, 2022

Comparison of Nationally Representative Samples of Rasburicase vs Allopurinol Post-Hyperuricemia Monotherapy in Hematological Malignancies: Significant Reduction in Tumor Lysis Syndrome Mortality with Rasburicase

October 14th, 2022

Tucatinib plus trastuzumab in patients (pts) with HER2-Positive Metastatic Colorectal Cancer (mCRC): Patient Reported Outcomes from MOUNTAINEER

October 5th, 2022

Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma: a randomized, phase 3 trial

September 30th, 2022

Primary Results from the Phase 3 Leap-002 Study: Lenvatinib plus Pembrolizumab versus Lenvatinib as First-Line Therapy for Advanced Hepatocellular Carcinoma

September 29th, 2022

Updated Efficacy and Safety of Lenvatinib Plus Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Advanced Endometrial Cancer: Study 309/KEYNOTE-775

September 28th, 2022

Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer (HER2+ mCRC): A Systematic Literature Review and Meta-Analysis of Clinical Outcomes

September 23rd, 2022

Association Between KRAS/STK11/KEAP1 Mutations and Outcomes in POSEIDON: Durvalumab ± Tremelimumab + Chemotherapy in Metastatic NSCLC

August 29th, 2022

Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study

August 4th, 2022

Primary Analysis of MOUNTAINEER: A Phase 2 Study of Tucatinib and Trastuzumab for HER2-positive mCRC

July 28th, 2022

Updated efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer

July 13th, 2022

Long-term efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase (TRK) fusion cancer

July 13th, 2022

Health-related quality of life in patients with relapsed/refractory multiple myeloma (RRMM) treated with teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody: Patient-reported outcomes in MajesTEC-1

July 13th, 2022

Hematologic Improvements With Ivosidenib + Azacitidine Compared to Placebo + Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia

July 7th, 2022

Updated Progression-Free Survival and Depth of Response in IKEMA, a randomized phase 3 trial of Isatuximab, Carfilzomib and Dexamethasone (Isa-Kd) vs Kd in Relapsed Multiple Myeloma

July 1st, 2022

Subcutaneous Epcoritamab in Patients with Relapsed or Refractory Large B-Cell Lymphoma (EPCORE NHL-1): Pivotal Results from a Phase 2 Study

June 30th, 2022

Final Analysis from AMPECT, an Open-Label Phase 2 Registration Trial of nab-SIROLIMUS for Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa)

June 22nd, 2022

Radiation Segmentectomy for Curative Intent of Unresectable HCC (RASER): A Prospective, Single Arm Study

June 17th, 2022

Long-Term Efficacy and Safety of Larotrectinib in Patients with Advanced TRK Fusion-Positive Thyroid Carcinoma

March 25th, 2022

Long-Term PFS From TIVO-3: Tivozanib (TIVO) Vs Sorafenib (SOR) in Relapsed/Refractory (R/R) Advanced RCC

March 22nd, 2022

Patient-Reported Outcomes and Changes in PSA in Patients With Advanced Prostate Cancer Treated With Apalutamide in the SPARTAN and TITAN Studies

March 15th, 2022

DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin plus Inducible T-cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma

March 14th, 2022

Safety and Efficacy of Tucatinib–Trastuzumab-Capecitabine Regimen for Treatment of Leptomeningeal Metastasis in HER2+ Breast Cancer: Results from TBCRC049, A Phase 2 Non-Randomized Study

March 11th, 2022

Attainment of Early, Deep Prostate-Specific Antigen Response in mCSPC: A Comparison of Patients Initiated on Apalutamide or Enzalutamide

March 8th, 2022

Rapid Readout: ARASENS: Darolutamide Versus Placebo in Combination With ADT and Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer

March 7th, 2022

Part 1 Results of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for RRMM

March 7th, 2022

Rapid Readout: Routine Clinical Practice Use of IRd in Patients With Relapsed/Refractory Multiple Myeloma (The INSURE Study)

February 24th, 2022

Rapid Readout: ctDNA Dynamics and Clinical Outcomes in the Adjuvant Management of Colorectal Cancer (GALAXY Study)

February 18th, 2022

Rapid Readout: HSCT With Omidubicel Achieved Robust Immune Reconstitution and Lower Rates of Severe Infection Compared to UCB Transplantation

February 10th, 2022

Rapid Readouts: Results of Phase 3 DREAMseq Trial in Advanced Melanoma

February 9th, 2022

Rapid Readout: Phase 1/2 Trial of Subcutaneous Epcoritamab With R-Squared in Patients with Relapsed or Refractory Follicular Lymphoma

February 8th, 2022

Rapid Readout: Post Hoc Analysis of Responses to Ponatinib in patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) by Baseline BCR::ABL1 Level and Baseline Mutation Status in the OPTIC Trial

January 28th, 2022

Addition of Isatuximab to RVd as Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma (GMMG-HD7)

January 27th, 2022

Rapid Readout: Community-Based United States MM-6 Study: Updated Efficacy and Safety, and Reasons for Premature Discontinuation

January 21st, 2022

Rapid Readout: Updated Results From CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucal In Patients With Relapsed/Refractory Multiple Myeloma

January 18th, 2022

Rapid Readout: Pirtobrutinib, A Highly Selective, Noncovalent (Reversible) BTK Inhibitor In Previously Treated CLL/SLL: Updated Results From The Phase 1/2 BRUIN Study

January 14th, 2022

Rapid Readout: Phase 3 Trial (EPCORE DLBCL-1) of Epcoritamab Versus Standard of Care in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

January 12th, 2022

Rapid Readout: Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results from the BRUIN Study

December 23rd, 2021

Rapid Readout: ZUMA‑7: Axicabtagene Ciloleucel versus Standard‑of‑Care Therapy in Patients with Relapsed/Refractory Large B‐Cell Lymphoma

December 23rd, 2021

Rapid Readout: AGILE: ivosidenib + azacitidine versus placebo + azacitidine in patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation

December 23rd, 2021

Rapid Readout: Safety and Efficacy of Menin Inhibition in Patients with MLL-Rearranged and NPM1 Mutant Acute Leukemia: SNDX-5613

December 23rd, 2021

Rapid Readout: Safety and Efficacy of CD37-Targeting Naratuximab Emtansine plus Rituximab in Diffuse Large B-Cell Lymphoma and Other Non-Hodgkin’s B-Cell Lymphomas

December 23rd, 2021

Rapid Readouts: Ibrutinib Plus Rituximab and Venetoclax Followed by Risk-Stratified Chemoimmunotherapy in Young Patients With Previously Untreated MCL

December 23rd, 2021

Rapid Readout: Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer with brain metastases (HER2CLIMB)

December 22nd, 2021

Rapid Readout: A Phase 3 Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

December 21st, 2021

Rapid Readout: Characterization of Bruton Tyrosine Kinase Inhibitor (BTKi)-Related Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)

December 21st, 2021

Rapid Readout: Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2+ Metastatic Breast Cancer: DESTINY-Breast03

December 21st, 2021

Rapid Readouts: Interim Analysis Results From the Phase 2 PRIMO Trial in R/R Peripheral T-Cell Lymphoma

December 20th, 2021

Rapid Readouts: Safety, Tolerability, and Efficacy of Axatilimab, a CSF-1R humanized antibody, for Chronic Graft-versus-Host Disease after 2 or more Lines of Systemic Treatment

December 17th, 2021

Rapid Readouts: 3-Year Overall Survival Update From the Phase 3 CASPIAN Study

November 9th, 2021

Rapid Readouts: Larotrectinib Prior Therapy and Performance Status Outcomes in Patients With Non-CNS TRK Fusion Cancer

November 1st, 2021

Rapid Readouts: Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase (TRK) Fusion-Positive Lung Cancer

November 1st, 2021

T-DXd Versus T-DM1 in HER2+ MBC: Results of DESTINY-Breast03

October 28th, 2021

Rapid Readout: T-DXd in Patients With HER2+ Unresectable or Metastatic Gastric or GEJ Following a Trastuzumab-Containing Regimen

October 27th, 2021

Rapid Readouts: Phase 1 Cohort of TRANSCEND-CLL-004 Study

October 21st, 2021

Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial

October 15th, 2021

ARCHES Final OS Analysis in mHSPC

October 15th, 2021

Rapid Readouts: ODENZA trial

October 7th, 2021

Rapid Readouts: IKEMA Subgroup Analysis in Relapsed Multiple Myeloma Patients With High-Risk Cytogenetics

September 24th, 2021

Rapid Readout: Assessment of Tucatinib vs Placebo in the HER2CLIMB Study of Pretreated Patients with HER2+ Metastatic Breast Cancer

September 9th, 2021

Rapid Readouts: Phase 3 ASCENT Study for Metastatic Triple-Negative Breast Cancer

August 11th, 2021

Rapid Readouts: Results from the Phase 3 VISION Study

August 11th, 2021

Rapid Readouts: First interim analysis of the ALPINE study: a phase III randomized trial of zanubrutinib vs. ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

July 14th, 2021

Rapid Readouts: Personalized versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomized, multicentre, open-label phase 2 trial

July 14th, 2021

Rapid Readouts: Safety and Efficacy of Pralsetinib in Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer: Update from the ARROW trial

July 13th, 2021

Rapid Readouts: Updated Results From the Phase 3 SIMPLIFY-1 Trial

July 8th, 2021

Rapid Readouts: SIMPLIFY-1 and SIMPLIFY-2 Trials

July 8th, 2021

Rapid Readouts: Final Analysis of Phase 3 TITAN Trial

July 6th, 2021

Rapid Readouts: Results of the SCOUT and NAVIGATE Trials

July 1st, 2021

Rapid Readouts: Results from two trials of TRK inhibitor, larotrectinib, in patients with TRK fusion-positive lung cancer

July 1st, 2021

Rapid Readouts: Updated data from a pooled analysis of larotrectinib in TRK fusion-positive cancers

July 1st, 2021

Rapid Readouts: Extended Follow-up From the Phase 3 ARAMIS trial

June 30th, 2021

Rapid Readouts: Treatment Preference Results From the Phase 2 ODENZA Trial

June 30th, 2021

Rapid Readouts: Final Results from Phase 3 ClarIDHy Trial

June 24th, 2021

Rapid Readouts: Updated Results and 5-Year Survival Outcomes From the PACIFIC Trial

June 18th, 2021

Rapid Readouts: Final Results From the Phase 3 PROTECTIVE-2 Trial

June 18th, 2021

Rapid Readouts: A Global Study of Advanced Dosimetry in the Treatment of HCC With Y 90 Glass Microspheres

May 12th, 2021

Rapid Readouts: Results from the Phase 3 CHRONOS-3 Trial for Relapsed iNHL

May 7th, 2021

Rapid Readouts: Phase 2 Trial of Pevonedistat Plus Azacitidine Versus Azacitidine in Higher-Risk MDS/CMML or LB AML

April 28th, 2021

Rapid Readouts: Phase 2 CodeBreak 100 Trial

March 4th, 2021

Rapid Readouts: Final Analysis Results From the Phase 3 TITAN Study

March 3rd, 2021

Rapid Readouts: Postoperative Chemotherapy Use and Outcomes from ADAURA

February 19th, 2021

Rapid Readouts: Patient-Reported Outcomes from ADAURA

February 19th, 2021

Rapid Readouts: Phase 1/2 Study of Epcoritamab in R/R B-cell NHL

January 28th, 2021

Rapid Readouts: Phase 2 JULIET Trial

January 26th, 2021

Rapid Readouts: Larotrectinib in Advanced TRK Fusion Thyroid Cancer

January 19th, 2021

Rapid Readouts: Efficacy of Novel Targeted Therapies Post-MURANO Study

January 18th, 2021

Rapid Readouts: The Phase 1/2 ANCHOR Trial for Melphalan Flufenamide in Relapsed/Refractory Multiple Myeloma

January 18th, 2021

Rapid Readouts: Phase 2 Study of Navitoclax in High-Risk Myelofibrosis

January 15th, 2021

Rapid Readouts: Results from the Phase 3 ANDROMEDA Study

January 14th, 2021

Rapid Readouts: Five-Year Analysis of MURANO Study

December 23rd, 2020

Rapid Readouts: Updated Results From KX-ORAX-001 Study

December 23rd, 2020

Rapid Readouts: Phase 1b/2 CARTITUDE-1 Study

December 23rd, 2020

Rapid Readouts: Updated Results From DESTINY-Breast01

December 23rd, 2020

Rapid Readouts: Momelotinib's Spleen, Symptom, and Anemia Efficacy

December 10th, 2020

Rapid Readouts: Long-Term Results from SIMPLIFY-1 and SIMPLIFY-2

December 10th, 2020

Rapid Readouts: Phase 3 VIALE-A Study

December 3rd, 2020

Rapid Readouts: Phase 1/2 KRYSTAL-1 Trial

November 18th, 2020

Rapids Readouts: Phase 3 CheckMate 238 Trial

October 30th, 2020

Rapid Readouts: TROPHY-U-01 Cohort 1 Final Results

October 14th, 2020

Rapid Readouts: Phase 3 HERO Trial

October 8th, 2020

Rapid Readouts: Phase 3 CheckMate 9ER Trial

October 7th, 2020

Rapid Readouts: Phase 3 ASCENT Study

October 5th, 2020

Rapid Readouts: Phase III PAOLA-1/ENGOT-ov25 Trial

August 24th, 2020

Rapid Readouts: Phase 1/2 Study Results of Liposomal Irinotecan and FOLFOX

July 17th, 2020

Rapid Readouts: Initial Results of the Phase III BOSTON Study

June 29th, 2020

Rapid Readouts: The SOLO2 / ENGOT Ov-21 Trial

June 25th, 2020

Rapid Readouts: Three-Year Update From CheckMate 227, Part 1

June 23rd, 2020

Rapid Readouts: Final Analysis of KEYNOTE-189

June 23rd, 2020

Rapid Readouts: Update of CARTITUDE-1

June 23rd, 2020

Rapid Readouts: The TIVO-3 Study of Tivozanib in Metastatic Renal Cell Carcinoma

June 19th, 2020

Rapid Readouts: CheckMate 9LA

June 16th, 2020

Rapid Readouts: JAVELIN Bladder 100 Phase III Interim Analysis

June 16th, 2020

Advertisement
Advertisement